Gilotrif (Afatinib)

FDA approves Gilotrif® (afatinib) as new oral treatment option for patients with squamous cell carcinoma of the lung.

  • Approval provides a new second-line treatment option for patients with the second largest sub-type of non-small cell lung cancer (NSCLC), representing about 20-30% of NSCLC cases
  • Approval is based on results of the LUX-Lung 8 study, which showed significantly improved overall survival and progression-free survival compared to Tarceva┬« (erlotinib) in patients with squamous cell carcinoma of the lung
  • Gilotrif is already approved in more than 60 countries for the treatment of patients with distinct types of EGFR mutation-positive NSCLC


No comments have been posted yet.